The Lab Without Walls: How Cloud Biology Proves Scientific Credibility
Problem: Biotech R&D Is So Fragmented Across Notebooks, Labs and Data Silos
Biotech research is a high-stakes game where speed and precision matters the most. Yet most labs are still bogged down by analog processes: handwritten notebooks, Excel spreadsheets and disconnected tools for sequencing, CRISPR design and collaboration.
This fragmentation leads to lost data, reproducibility crises and delays in drug development — with failure rates as high as 90% in preclinical stages (Deloitte 2025 Biotech Report).
The “reproducibility crisis” is real: a 2025 Nature survey found out 70% of researchers have failed to replicate published experiments. Siloed data also hampers collaboration in a field where teams are often global and interdisciplinary—Benchling is addressing this by digitizing the entire R&D workflow in the cloud.
Benchling Is Not Just Digitizing Labs — It’s Redefining How Science Proves Both Reproducibility and Trust
Benchling is not a mere lab notebook app. It is the credibility layer for modern biology — a unified cloud platform that ensures every experiment is traceable, reproducible and shareable. In 2026, as AI and gene editing accelerate discovery, trust in data becomes paramount—Benchling is building the infrastructure that makes biotech credible at a large scale.
Solution: Unified Cloud Platform for Experiments, Data and Collaboration
Benchling’s platform integrates:
1.Digital lab notebooks: Structured entries with auto-timestamping, version control and searchability.
2.Molecular biology tools: Design CRISPR guides, simulate protein structures and manage inventories in one place.
3.Data management: Central repository for sequencing results, assays and workflows — with AI-powered insights for patterns and anomalies.
4.Collaboration features: Real-time sharing, comments and audit trails for teams across labs or continents.
5.It also supports 1,000+ biotech companies, including Moderna, Regeneron and Ginkgo Bioworks, with seamless integration to lab equipment and databases.
Proof of Credibility: Used by 1,000+ Biotech Companies, Including Moderna and Regeneron
Benchling’s proof is in its adoption because;
1.Over 1,000 companies and 200,000+ scientists use the platform (2025 figures).
2.Moderna credited Benchling for streamlining mRNA design during the COVID vaccine development.
3.Regeneron uses it for antibody discovery, reporting 30–50% faster workflows.
4.Ginkgo Bioworks integrates it for bioengineering at scale, reducing data errors by 85%.
5.The platform is SOC 2, ISO 27001 certified and compliant with FDA 21 CFR Part 11 for electronic records.
Impact: Scientists Gain Speed and Transparency; Investors See Reproducible and Scalable Innovation
For scientists:
•40–60% reduction in administrative time (Benchling 2025 case studies).
•Improved reproducibility: 92% of users report easier replication of experiment.
For investors:
•Faster R&D cycles mean quicker time-to-market for drugs and therapies.
•Transparent data builds trust in due diligence — key for biotech valuations.
•Scalable innovation: Companies like Benchling-backed startups raised $15B+ in 2025.
Overall, Benchling is helping biotech move from siloed science to collaborative credible discovery.
Benchling as the Future of Cloud Biology
The lab of the future has no walls. Benchling is proving that cloud biology can make science faster, more collaborative and above all, more trustworthy.
In an industry where reproducibility is the gold standard, Benchling is the platform that makes it achievable. The future of biotech isn’t just about breakthroughs — it is about breakthroughs you can trust.
Comments
Post a Comment